Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD

William Vaughn McCall; Anilkumar Pillai; Chirayu D. Pandya; Laryssa McCloud; Jason A. Moraczewski; Liniya Tauhidul; Nagy A. Youssef; Doug Case; Peter B. Rosenquist

doi:10.1016/j.heliyon.2019.e01709

Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD

William Vaughn McCall, Anilkumar Pillai, Chirayu D. Pandya, Laryssa McCloud, Jason A. Moraczewski, Liniya Tauhidul, Nagy A. Youssef, Doug Case, Peter B. Rosenquist

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Overactivity of the noradrenergic (NE) system within the central nervous system (CNS) has been postulated as a key pathophysiology of posttraumatic stress disorder (PTSD). The activity of the enzyme salivary α-amylase (sAA) has been proposed as an indirect measure of CNS NE activity, and sAA is elevated in PTSD. As an antagonist of the α-1 NE receptor, prazosin would be expected to alter sAA values in PTSD patients. However, given its short half-life, it is not clear whether bedtime doses would have an effect on daytime sAA. In the present study, we assayed daytime sAA in 20 suicidal PTSD patients who were randomized to prazosin versus placebo at bedtime-only, and found no effect in daytime sAA. These findings are consistent with studies showing an advantage for twice daily dosing of prazosin in PTSD.

Original language	English
Article number	e01709
Journal	Heliyon
Volume	5
Issue number	5
DOIs	https://doi.org/10.1016/j.heliyon.2019.e01709
State	Published - May 2019

Bibliographical note

Publisher Copyright:
© 2019

Keywords

Psychiatry

ASJC Scopus subject areas

General

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.heliyon.2019.e01709

Cite this

@article{ec037291be5a444c9b78ae73c10293ab,

title = "Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD",

abstract = "Overactivity of the noradrenergic (NE) system within the central nervous system (CNS) has been postulated as a key pathophysiology of posttraumatic stress disorder (PTSD). The activity of the enzyme salivary α-amylase (sAA) has been proposed as an indirect measure of CNS NE activity, and sAA is elevated in PTSD. As an antagonist of the α-1 NE receptor, prazosin would be expected to alter sAA values in PTSD patients. However, given its short half-life, it is not clear whether bedtime doses would have an effect on daytime sAA. In the present study, we assayed daytime sAA in 20 suicidal PTSD patients who were randomized to prazosin versus placebo at bedtime-only, and found no effect in daytime sAA. These findings are consistent with studies showing an advantage for twice daily dosing of prazosin in PTSD.",

keywords = "Psychiatry",

author = "McCall, {William Vaughn} and Anilkumar Pillai and Pandya, {Chirayu D.} and Laryssa McCloud and Moraczewski, {Jason A.} and Liniya Tauhidul and Youssef, {Nagy A.} and Doug Case and Rosenquist, {Peter B.}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = may,

doi = "10.1016/j.heliyon.2019.e01709",

language = "English",

volume = "5",

number = "5",

}

TY - JOUR

T1 - Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD

AU - McCall, William Vaughn

AU - Pillai, Anilkumar

AU - Pandya, Chirayu D.

AU - McCloud, Laryssa

AU - Moraczewski, Jason A.

AU - Tauhidul, Liniya

AU - Youssef, Nagy A.

AU - Case, Doug

AU - Rosenquist, Peter B.

PY - 2019/5

Y1 - 2019/5

N2 - Overactivity of the noradrenergic (NE) system within the central nervous system (CNS) has been postulated as a key pathophysiology of posttraumatic stress disorder (PTSD). The activity of the enzyme salivary α-amylase (sAA) has been proposed as an indirect measure of CNS NE activity, and sAA is elevated in PTSD. As an antagonist of the α-1 NE receptor, prazosin would be expected to alter sAA values in PTSD patients. However, given its short half-life, it is not clear whether bedtime doses would have an effect on daytime sAA. In the present study, we assayed daytime sAA in 20 suicidal PTSD patients who were randomized to prazosin versus placebo at bedtime-only, and found no effect in daytime sAA. These findings are consistent with studies showing an advantage for twice daily dosing of prazosin in PTSD.

AB - Overactivity of the noradrenergic (NE) system within the central nervous system (CNS) has been postulated as a key pathophysiology of posttraumatic stress disorder (PTSD). The activity of the enzyme salivary α-amylase (sAA) has been proposed as an indirect measure of CNS NE activity, and sAA is elevated in PTSD. As an antagonist of the α-1 NE receptor, prazosin would be expected to alter sAA values in PTSD patients. However, given its short half-life, it is not clear whether bedtime doses would have an effect on daytime sAA. In the present study, we assayed daytime sAA in 20 suicidal PTSD patients who were randomized to prazosin versus placebo at bedtime-only, and found no effect in daytime sAA. These findings are consistent with studies showing an advantage for twice daily dosing of prazosin in PTSD.

KW - Psychiatry

UR - http://www.scopus.com/inward/record.url?scp=85065441544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065441544&partnerID=8YFLogxK

U2 - 10.1016/j.heliyon.2019.e01709

DO - 10.1016/j.heliyon.2019.e01709

M3 - Article

AN - SCOPUS:85065441544

SN - 2405-8440

VL - 5

JO - Heliyon

JF - Heliyon

IS - 5

M1 - e01709

ER -

Bedtime doses of prazosin do not affect daytime salivary amylase markers in PTSD

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this